Merck & Co. (MRK) 8-K Regulation FD Disclosure

Exhibit 99.2

MERCK & CO., INC.
FRANCHISE / KEY PRODUCT SALES⁽¹⁾ — GAAP TO SUPPLEMENTAL COMBINED NON-GAAP RECONCILIATION
(AMOUNTS IN MILLIONS)

The following Table reflects Supplemental Combined Non-GAAP sales which are adjusted to reflect the periods presented of Merck and Schering-Plough combined results as if the merger closed as of January 1, 2008.

													Supp. Comb. %
					Supp. Comb.						Supp. Comb.		Change 4Q09 &
	GAAP		Adjustment		Non-GAAP		GAAP		Adjustment		Non-GAAP		1Q10 vs 4Q08 &
	4Q09 & 1Q10		4Q09 & 1Q10		4Q09 & 1Q10		4Q08 & 1Q09		4Q08 & 1Q09		4Q08 & 1Q09		1Q09
TOTAL GLOBAL HUMAN HEALTH(2)		18,866		1,733		20,598		10,556		8,620		19,177		7
Bone, Resp., Imm., & Dermatology
Singulair		2,425				2,425		2,180				2,180		11
Remicade		1,105		205		1,309				1,009		1,009		30
Nasonex		485		121		606				586		586		3
Cardiovascular
Zetia/Vytorin		1,793		409		2,202		37		2,075		2,112		4
Zetia		933		215		1,148		3		1,065		1,068		7
Vytorin		860		194		1,054		34		1,009		1,044		1
Diabetes & Obesity
Januvia/Janumet		1,472				1,472		1,072				1,072		37
Januvia		1,069				1,069		824				824		30
Janumet		403				403		248				248		62
Infectious Disease
Isentress		466				466		278				278		68
Mature Brands
Cozaar / Hyzaar		1,737				1,737		1,721				1,721		1
Oncology
Temodar		462		103		565				489		489		16
Vaccines
ProQuad, M-M-R II and Varivax		652				652		547				547		19
Gardasil		510				510		548				548		-7
ANIMAL HEALTH		1,203		265		1,468				1,295		1,295		13
CONSUMER CARE(2)		528		83		611				603		603		1

(1)	Only select products are shown. Sales reflect the then current foreign exchange rates.
(2)	Global Human Health includes worldwide prescription pharmaceutical sales and consumer product sales excluding the US and Canada. Consumer Care includes US and Canada consumer product sales.

Note: The Company is providing Supplemental Combined Non-GAAP sales to reflect the revenues of the company’s product sales on a comparable basis to periods prior to the merger. Merck has defined Supplemental Combined Non-GAAP sales as GAAP sales adjusted to reflect the periods presented of Merck and Schering-Plough performance as if the merger closed at the beginning of the periods indicated in this table. This supplemental information is provided to enhance investors’ understanding of the company’s sales performance. This information should be considered in addition to, but not in lieu of, sales reported in accordance with GAAP.